CD8A and neoplasm: Loss of non-hematopoietic PD-L1 and inhibition of IFNγ signaling on peripheral LECs, thus preventing PD-L1 upregulation, improved the persistence of anti-tumor CD8+ T cell-mediated tumor killing and overall survival in melanoma-bearing mice (121).